Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Drews discusses the case histories of several modern innovative drugs — bevacizumab, COX2 inhibitors, enfuvirtide, imatinib and natalizumab — and considers whether they can provide lessons for improving research and development strategies.
'Push' or 'pull' strategies have been only partially successful in stimulating vaccine R&D for neglected diseases. Mossialos and Brogan propose an alternative – a hybrid model in which purchasers share the development risk in exchange for reduced vaccine prices.
Expertise in integrativein vivopharmacology has been dwindling for several years. Michael Collis looks at recent initiatives to address the current skills deficit in academia and industry by providing funding for education and practical experience in this crucial discipline.
